Tonix Pharmaceuticals Presents Positive Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder (PTSD) ...
Study Successfully Identified Effective and Well-tolerated Dose for Registration Studies Phase 3 Clinical Program Planned NEW YORK, May 31, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), which is developing next- …